Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2125694 | 0.88 | S1PR1 (0.57) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2129295 | 0.86 | S1PR1 (0.54) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2124655 | 0.83 | S1PR1 (0.71) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2125956 | 0.83 | S1PR1 (0.66) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2132588 | 0.82 | S1PR1 (0.61) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2121974 | 0.81 | S1PR1 (0.55) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2126741 | 0.80 | S1PR1 (0.79) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2121730 | 0.80 | S1PR1 (0.73) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2129099 | 0.79 | S1PR1 (0.59) | S1PR1S1PR3S1PR5 | |
| SCHEMBL2121808 | 0.79 | S1PR1 (0.57) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443111-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010145203-A1 | 1,2,4-OXADIAZOL DERIVATIVES, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS SPHINGOSINE 1-PHOSPHATE 1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |